Takara Bio enters into a license agreement of RetroNectin with Fondazione Telethon ETS
Kusatsu/Shiga, Japan—September 25, 2023—Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS (“Telethon”) (https://www.telethon.it/en), Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin. Under this agreement, Takara Bio provides Telethon with reliable supplies of RetroNectin.
The technologies licensed to Telethon are based on Takara Bio’s proprietary RetroNectin method, which includes a technology enabling highly efficient gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency. With such advantages, RetroNectin method is one of the mostly used standard protocols utilized for “Engineered Gene Therapy”, which includes promising TCR and CAR gene therapies recently raising higher expectations, as well as “Hematopoietic stem cell Gene Therapy”.
Under the agreement signed with Takara Bio, Telethon is allowed to use RetroNectin for production of its cell & gene therapy products, one of which is Strimvelis, a rare disease treatment targeting Adenosine deaminase deficiency.
Takara Bio is promoting supply of RetroNectin to clinical development of engineered gene and cell therapy actively pursued worldwide in recent years, and expects higher sales growth in the future.
Corporate Department, Takara Bio Inc.
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.
About Takara Bio Inc.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.